KRAS and cancer: However, the emergence of covalent inhibitors to target KRAS has enabled the development of PROTACs capable of inducing endogenous KRASG12C degradation in cancer cells, such as LC-2 that couples the covalent KRASG12C inhibitor adagrasib to the von Hippel–Lindau (VHL) ligand (82).